Landscape Capital Management L.L.C. Invests $1.02 Million in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Landscape Capital Management L.L.C. bought a new stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 25,435 shares of the company’s stock, valued at approximately $1,019,000.

Other hedge funds have also bought and sold shares of the company. Grandfield & Dodd LLC raised its position in shares of Ionis Pharmaceuticals by 2.2% during the 3rd quarter. Grandfield & Dodd LLC now owns 34,813 shares of the company’s stock valued at $1,395,000 after buying an additional 760 shares in the last quarter. Advisors Asset Management Inc. increased its stake in Ionis Pharmaceuticals by 21.0% in the third quarter. Advisors Asset Management Inc. now owns 6,140 shares of the company’s stock valued at $246,000 after acquiring an additional 1,066 shares during the last quarter. Commerce Bank raised its position in Ionis Pharmaceuticals by 1.6% during the third quarter. Commerce Bank now owns 77,553 shares of the company’s stock valued at $3,107,000 after purchasing an additional 1,211 shares in the last quarter. Prospera Private Wealth LLC bought a new stake in Ionis Pharmaceuticals during the third quarter worth about $42,000. Finally, Quest Partners LLC boosted its holdings in shares of Ionis Pharmaceuticals by 94.8% in the 3rd quarter. Quest Partners LLC now owns 2,674 shares of the company’s stock worth $107,000 after purchasing an additional 1,301 shares in the last quarter. 93.86% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on IONS shares. The Goldman Sachs Group boosted their target price on Ionis Pharmaceuticals from $33.00 to $37.00 and gave the stock a “sell” rating in a research report on Friday, August 2nd. Guggenheim lowered their price objective on shares of Ionis Pharmaceuticals from $70.00 to $65.00 and set a “buy” rating for the company in a report on Wednesday, October 9th. Barclays increased their target price on shares of Ionis Pharmaceuticals from $45.00 to $51.00 and gave the company an “equal weight” rating in a report on Friday, August 2nd. Wells Fargo & Company lowered their price target on shares of Ionis Pharmaceuticals from $82.00 to $77.00 and set an “overweight” rating for the company in a research note on Thursday, November 7th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $70.00 price objective on shares of Ionis Pharmaceuticals in a research note on Thursday, September 26th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Ionis Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $60.65.

Insiders Place Their Bets

In related news, CEO Brett P. Monia sold 6,630 shares of the business’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $38.05, for a total transaction of $252,271.50. Following the transaction, the chief executive officer now owns 167,393 shares in the company, valued at $6,369,303.65. The trade was a 3.81 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Eric Swayze sold 1,194 shares of the firm’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $37.92, for a total transaction of $45,276.48. Following the completion of the sale, the executive vice president now owns 33,713 shares of the company’s stock, valued at $1,278,396.96. This trade represents a 3.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 8,197 shares of company stock worth $315,310. 2.71% of the stock is currently owned by corporate insiders.

Ionis Pharmaceuticals Stock Performance

Shares of IONS stock opened at $34.01 on Friday. The firm has a market capitalization of $5.37 billion, a price-to-earnings ratio of -13.94 and a beta of 0.39. The stock has a fifty day moving average of $38.87 and a 200 day moving average of $42.52. Ionis Pharmaceuticals, Inc. has a 52 week low of $33.33 and a 52 week high of $54.44. The company has a quick ratio of 8.82, a current ratio of 8.91 and a debt-to-equity ratio of 1.86.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.